Method of using exendin and GLP-1 to affect the central nervous system
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Dec 8, 1998
Grant Date -
N/A
app pub date -
Mar 3, 1997
filing date -
Mar 3, 1997
priority date (Note) -
Expired
status (Latency Note)
Importance
Abstract
Agonists of the incretin GLP-1 have been found to have a sedative or anxiolytic effect on the mammalian central nervous system. Additionally, exendin has been found to have an independent sedative effect on the mammalian central nervous system. Conversely, antagonists of GLP-1 increase nervous system activity. The invention relates, in one aspect, to the use of GLP-1 agonists and antagonists to affect the arousal state of the mammalian central nervous system. The invention also relates to novel transgenic mammals in which the GLP-1 receptor gene has been disrupted.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully